New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Research: Molecular differences in Biothera beta-glucans affect immune cell responses

Biothera announced that the new in vitro and in vivo studies of Biothera beta-glucans published in the current issue of the journal Blood demonstrates the importance of molecular structure in designing effective immunotherapies.

New in vitro and in vivo studies of Biothera beta-glucans published in the current issue of the journal Blood demonstrate the importance of molecular structure in designing effective immunotherapies, the company announced.

The paper confirms research published in the April issue of Nature that found that differences in yeast-derived beta-glucan structures determine their ability to bind to receptors on innate immune cells and the specific immune responses that result.

Biothera’s soluble and particulate beta-glucans depend on different receptors to elicit their biological activities. The Dectin-1 pathway is essential for Biothera’s particulate beta-glucan to mediate immune modulatory effects on dendritic cell activation, macrophage phagocytosis, and CD4 (TH1) and CD8 (Cytotoxic) T-lymphocyte activation. In contrast, Biothera’s soluble beta-glucan is dependent on Complement Receptor binding to elicit neutrophil-mediated responses to antibody targeted cells and does not directly effect T-cell activation.

“These data demonstrate how different beta-glucan structures affect immunomodulatory mechanisms,” said principal investigator Jun Yan, M.D., Ph.D. of the Department of Medicine, Co-director of Tumor Immunobiology Program, James Graham Brown Cancer Center, University of Louisville School of Medicine in Louisville, Kentucky. “Biothera’s ability to produce and characterize these beta-glucan compounds was critical to this research.”

“As demonstrated in previous research, ‘structure matters’ to beta-glucan binding and initiation of differential immunomodulatory responses,” said William Grossman, M.D., Ph.D., Biothera senior vice president of Research & Development. “Our commitment to researching the biological mechanisms underpinning the activity of our compounds will lead to even more effective pharmaceuticals and food-grade ingredients.”

The paper is entitled, “Differential Pathways Regulating Innate and Adaptive Anti-tumor Immune Responses by Particulate and Soluble Yeast-derived b-Glucans.” The research was conducted under the leadership of Dr. Yan.

About Biothera, the Immune Health Company

Biothera is a biotechnology company dedicated to improving immune health. The company is commercializing its unique technology platform through two business groups. Biothera’s Pharmaceutical Group is conducting multiple clinical trials for the development of an immune modulating drug that mobilizes the innate immune system to fight most types of cancer. The company’s Healthcare Group is a leading provider of natural immune health ingredients for the functional food and beverage, dietary supplement, cosmetic and animal nutrition markets.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.